VJHemOnc is committed to improving our service to you

MDS 2020 | Prognosis and treatment in high-risk MDS

VJHemOnc is committed to improving our service to you

Drorit Merkel

Drorit Merkel, MD, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel, discusses the unmet need for novel treatments in high-risk myelodysplastic syndromes (MDS), with reference to the advantages and disadvantages of using azacitidine. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter